PANCREAS CANCER

Exocrine pancreas cancer

The pancreas cancer microenvironment.

Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and targeted therapies have provided only limited efficacy for patients with PDA to date. One contributing factor to the failure of systemic therapies may be the abundant tumor stromal content that is the characteristic of PDA. T...

Cancer of the pancreas.

The malignant growth may originate either in the duct cells or acini of the gland, or in the islets of Langerhans. Cancer of the islet cells is uncommon and is discussed in a later section. About 80% of tumours are adenocarcinomas which arise from ductular epithelium. The neoplasm is hard and scirrhous and the cells are columnar or cuboidal with clear-cut cellular outlines. Cancers arising from...

Staging cancer of the pancreas

Pancreatic carcinoma is the fourth cause of death from cancer in the United States, with a survival rate at 5 years of less than 5%. About 60% of tumors originate at the head of the pancreas, 15% in the body, 5% in the tail; 20% are diffuse within the pancreas. This article discusses the imaging and staging of pancreatic cancer.

Borderline and Unresectable Pancreas Cancer

Expert Panel on Radiation Oncology–Gastrointestinal: William Small Jr, MD; John P. Hayes, MD; W. Warren Suh, MD, MPH; May Abdel-Wahab, MD, PhD; Ross A. Abrams, MD; Nilofer Azad, MD; Prajnan Das, MD; Jadranka Dragovic, MD; Karyn A. Goodman, MD; Salma K. Jabbour, MD; William E. Jones III, MD; Andre A. Konski, MD, MBA, MA; Albert C. Koong, MD, PhD; Rachit Kumar, MD; Percy Lee, MD; Timothy M. Pawli...